We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our Privacy Policy.
Dr. Edward Ainscow
Director, Genomics Institute of the Novartis Research Foundation.
Sylvie Jezequel-Sur
MS, Associate Principal Scientist, Merck & Co.
R. Jason Kirby
MS, Senior Associate Scientist, Sanford Burnham Prebys Medical Discovery Institute.
GPCRs constitute the largest class of protein targets for pharmacological manipulation. However, technical challenges persist in the rapid screening of GPCR agonists and antagonists. A panel of experts will discuss advances in high-throughput screening for GPCR drug discovery.
©2023 Revvity - All rights reserved